Results for tag: "Diabetic Kidney Disease"

In the field of endocrinology, Diabetic Kidney Disease (DKD), also known as Diabetic Nephropathy, stands as a serious and prevalent complication arising from diabetes, primarily both type 1 and type 2. It reflects damage to the kidney's filtration system caused by the long-term effects of high blood sugar levels. DKD is a major focus within endocrinology due to its impact on patient morbidity and the increased risk of kidney failure it imposes. Management of DKD involves strict glycemic control, blood pressure management, and often the use of medications that protect kidney function. Within the market, treatments are geared towards slowing the progression of the disease, with research continually ongoing to develop improved therapeutic options and strategies to prevent the onset of the condition in diabetic patients. The market comprises a mix of pharmaceutical interventions, monitoring technologies, and potential biotechnological innovations aimed at both treatment and improved quality of life. Several pharmaceutical and biotechnology companies have a presence in the Diabetic Kidney Disease market. These include major players such as AstraZeneca, Boehringer Ingelheim, and Merck, who offer medications that address the management of blood glucose levels and protect kidney function. Firms like Eli Lilly and Sanofi also contribute with their range of diabetes care products. Additionally, companies like Novo Nordisk and Johnson & Johnson are involved in the research and development of novel treatments to combat the disease. In the biotech sphere, smaller companies like FibroGen Show Less Read more